Stay always up-to-date
with our corporate news

News Archive


Ypsomed is establishing a new subsidiary in Austria

The new Group company is based in Vienna and is led by Patrick Heil, who combines this role with that of General Manager for Switzerland.

Press Release - Semiannual Results

Operating profit impacted by market expansion activities and currency effects

Strategic acquisition - Ypsomed strengthens its position in the diabetes sector

Ypsomed today announces the acquisition of ICU Medical, Inc.’s Orbit diabetes infusion set business. With this acquisition, Ypsomed strengthens its position in the diabetes sector.

Ypsomed insulin pen to be launched in Germany by B. Braun

B. Braun is to distribute the reusable insulin pen Omnifill, developed by the Burgdorf-based diabetes specialist, together with its human insulins

Ypsomed strengthens company management

The Technology and Operations division are now directly represented on the management board of the Burgdorf-based diabetes specialist

Move from the Main to the Domestic Standard segment of the SIX Swiss Exchange

Shares of Ypsomed Holding AG now in the Domestic Standard of the SIX Swiss Exchange

Ypsomed presents new product innovation at EASD in Lisbon

In early 2012, Ypsomed is to launch the second generation OmniPod insulin patch pump

Reporting standards: switch from IFRS to Swiss GAAP ARR

Ypsomed Holding AG to switch financial reporting standards from IFRS to Swiss GAAP ARR

Change of CEO at Ypsomed

Richard Fritschi is leaving Ypsomed. Dr. h. c. Willy Michel will assume the roles of CEO and chairman of the Ypsomed Group.

Ypsomed achieves strong growth with mylife Diabetescare

In Germany, already one in three new pump users decide to use the mylife OmniPod insulin patch pump

Ypsomed 2010/11 business year

Ypsomed is on the right track – However, the transformation takes longer

Ypsomed expands the mylife Diabetescare product range

The new mylife Roto infusion set with 360-degree freedom of movement